NEW YORK (GenomeWeb News) - Lexicon Genetics today said it has entered into agreements with unspecified investors to purchase up to 10,582,011 shares of its stock.
The Woodlands, Texas-based biopharmaceutical company said "select institutional investors" agreed to purchase the stock at a price of $3.78 per share, and that it expects net proceeds of up to $37.5 million.
The agents for the placement were Banc of America Securities and Lazard Capital Markets.
Already have a GenomeWeb or 360Dx account?Login Now.
American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.
A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.
Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.
In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.